Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) Products under Development by Stage of Development | 8 | 1 |
| Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) Products under Development by Therapy Area | 9 | 1 |
| Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) Products under Development by Indication | 10 | 1 |
| Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) Products under Development by Companies | 13 | 2 |
| Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) Therapeutics Assessment | 15 | 4 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 1 |
| Assessment by Route of Administration | 17 | 1 |
| Assessment by Molecule Type | 18 | 1 |
| Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) Companies Involved in Therapeutics Development | 19 | 5 |
| AstraZeneca Plc | 19 | 1 |
| C&C Research Laboratories | 20 | 1 |
| CymaBay Therapeutics, Inc. | 21 | 1 |
| Jiangsu Hengrui Medicine Co., Ltd. | 22 | 1 |
| Wellstat Therapeutics Corporation | 23 | 1 |
| Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) Drug Profiles | 24 | 13 |
| (allopurinol + lesinurad) Drug Profile | 24 | 1 |
| arhalofenate Drug Profile | 25 | 5 |
| JPH-367 Drug Profile | 30 | 1 |
| RLBN-1001 Drug Profile | 31 | 1 |
| Small Molecules to Inhibit Human Uric Acid Transporter 1 for Hyperuricemia Drug Profile | 32 | 1 |
| URC-102 Drug Profile | 33 | 1 |
| verinurad Drug Profile | 34 | 2 |
| WT-2107 Drug Profile | 36 | 1 |
| Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) Dormant Projects | 37 | 1 |
| Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) Discontinued Products | 38 | 1 |
| Solute Carrier Family 22 Member 12 (Organic Anion Transporter 4 Like Protein or Renal Specific Transporter or RST or Urate Anion Exchanger 1 or SLC22A12) Featured News &Press Releases | 39 | 12 |
| Mar 28, 2016: CymaBay Therapeutics Announces Acceptance of Arhalofenate Phase 2b Gout Study Manuscript in Arthritis and Rheumatology | 39 | 1 |
| Jan 20, 2016: CymaBay Therapeutics Announces Successful Completion of End-of-Phase 2 Discussions With FDA for Arhalofenate | 40 | 1 |
| Nov 05, 2015: CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology Annual Meeting, November 6 - 11 | 41 | 1 |
| Aug 06, 2015: CymaBay Strengthens the Intellectual Property of Arhalofenate With Issuance of Two New Patents | 42 | 1 |
| Jun 12, 2015: CymaBay Therapeutics Presents Poster at EULAR 2015 | 42 | 1 |
| Mar 23, 2015: CymaBay Therapeutics to Host Key Opinion Leader Meeting on March 27 in New York City | 43 | 1 |
| Mar 03, 2015: Vince &Associates Clinical Research Completes CymaBay Therapeutics Clinical Trial of Arhalofenate in Combination with Febuxostat | 44 | 1 |
| Feb 24, 2015: CymaBay Therapeutics Announces Positive Results From Its Phase 2b Clinical Study Demonstrating That Arhalofenate Met the Primary Endpoint of Reduction in Gout Flares | 44 | 1 |
| Jan 12, 2015: Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat | 45 | 2 |
| Sep 29, 2014: CymaBay Completes Enrollment in its Phase 2b Study of Arhalofenate in Patients with Gout | 47 | 1 |
| Mar 26, 2014: CymaBay Initiates Arhalofenate Phase 2b Gout Study | 47 | 1 |
| Dec 08, 2011: Metabolex Announces Positive Results From Clinical Study Of Arhalofenate In Combination With Febuxostat | 47 | 1 |
| Nov 07, 2011: Ardea Biosciences Presents Initial Clinical Results For RDEA3170 At 2011 ACR/ARHP Annual Scientific Meeting | 48 | 1 |
| Nov 01, 2011: Metabolex To Present Data On Arhalofenate At 2011 ACR/AHP Annual Scientific Meeting | 49 | 1 |
| May 19, 2011: Metabolex Initiates Phase II Trial Of Arhalofenate For Treatment Of Gout | 49 | 2 |
| Appendix | 51 | 2 |
| Methodology | 51 | 1 |
| Coverage | 51 | 1 |
| Secondary Research | 51 | 1 |
| Primary Research | 51 | 1 |
| Expert Panel Validation | 51 | 1 |
| Contact Us | 51 | 1 |
| Disclaimer | 52 | 1 |